AML

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

The KOMET-007 trial reveals promising safety and efficacy of ziftomenib combined with venetoclax and azacitidine for relapsed/refractory AML patients.

A new combination therapy shows promising results in achieving durable remission for patients with NPM1-mutated acute myeloid leukemia.

The SAVE regimen demonstrates promising efficacy in newly diagnosed AML, achieving high response rates but raises concerns about myelosuppression.

A clinical trial of the menin inhibitor DS-1594b in patients with relapsed leukemia has been terminated due to inefficacy, revealing safety challenges and insights for future therapies.

A recent trial shows omacetaxine and venetoclax combination benefits patients with MDS but not AML, highlighting the need for further research.

In an interview with Targeted Oncology, Justin Watts, MD spoke about the long-term durability findings with olutasidenib and the next steps for IDH inhibitors in AML.

In an interview with Targeted Oncology, Justin Watts, MD, discussed the outcomes of a trial of the IDH1 inhibitor olutasidenib in patients with myelodysplastic syndrome.

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

If approved, ziftomenib could be the first FDA-approved Menin inhibitor for relapsed/refractory acute myeloid leukemia with an NPM1 mutation.

The first patient in a trial received oral zelenirstat, a N-myristoyltransferase inhibitor, to determine its safety and tolerability in relapsed/refractory AML.

Patients with AML aged 80 years and older face poor survival despite treatment advances, highlighting the need for improved, equitable care strategies and tailored treatment approaches.

The phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia can proceed without modifications, based on findings from the prespecified interim analysis of the study.

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.

BL-M11D1, a CD33-binding antibody-drug conjugate, is being evaluated for the treatment of patients with acute myeloid leukemia.

Sangeetha Venugopal, MD, MS, discussed the evolving landscape of acute myeloid leukemia treatment as well as unmet needs among these patients.

Following a futility analysis, the phase 2 SELECT-AML-1 trial of tamibarotene combined with venetoclax and azacitidine in newly diagnosed RARA-overexpressed acute myeloid leukemia will discontinue enrollment.

The FDA has granted a rare pediatric disease designation to SLS009 for treating pediatric acute myeloid leukemia.

The completion of the End of Phase 2 meeting for the phase 1B/2 trial of annamycin and cytarabine in acute myeloid leukemia has been announced.

The FDA granted a rare pediatric disease designation to a promising new drug, SLS009, for the treatment of pediatric leukemia.

An investigational new drug application for lomonitinib has been cleared by the FDA for FLT3-mutated relapsed/refractory AML treatment, and a phase 1 trial evaluating the agent will begin in the US.

A phase 3 study evaluating uproleselan in relapsed/refractory acute myeloid leukemia missed its primary end point of overall survival.